Objective: Mutations in the high-temperature requirement A serine peptidase 1 (HTRA1) gene were studied in a Chinese family with cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL). Methods: Exons 1-9 of the HTRA1 gene were amplified and bidirectionally sequenced in a Chinese family with CARASIL. Mutation effects were analysed by three-dimensional modelling of the serine protease HTRA1 protein.
Introduction
Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) is an uncommon familial nonhypertensive cerebral small-vessel arteriopathy characterized by early adulthood onset of subcortical infarcts, alopecia, spondylosis and progressive cognitive impairment. [1] [2] [3] Recurrent stroke or gradual deterioration, and cognitive deficit, are the main neural manifestations of CARASIL. Alopecia and spondylosis are the main clinical manifestations of CARASIL outside the neural system, and are features that differ from other cerebral small-vessel diseases. [1] [2] [3] [4] Studies have found that the pathological features of CARASIL, for example arteriosclerosis, loss of vascular smooth muscle and hyaline degeneration of the tunica media, are similar to those in nonhereditary ischaemic cerebral small-vessel disease. 2, 5 A study involving five consanguineous Japanese families with CARASIL mapped the locus associated with CARASIL to chromosome 10q, which is the location of the high-temperature requirement A serine peptidase 1 (HTRA1) gene encoding serine protease HTRA1 protein. 3 Serine protease HTRA1 can suppress the signalling by transforming growth factor (TGF)-b family members, and this suppression has been associated with vascular diseases including CARASIL. 2, [6] [7] [8] [9] [10] [11] CARASIL has been associated with mutations in the HTRA1 gene in several families. 2, [12] [13] [14] Seven mutations (p.A252T, p.R274Q, p.G295R, p.V297M, p.R302X, p.R370X and p.L364P) have been identified in exons 3, 4 and 6 of the HTRA1 gene in patients with CARASIL. 2, [12] [13] [14] The first novel mutation to be found in a Chinese pedigree was c.1091 T 4 C (p.L364P) in exon 6 of the HTRA1 gene; however, no further mutations have been confirmed in Chinese patients with CARASIL. 14 The present study assessed the clinical and molecular genetic characteristics of a Chinese family with CARASIL to reveal the genetic causes of CARASIL in this family, and assess the role of HTRA1 gene mutations in its pathogenesis.
Patients and methods

Study participants
The pedigree of a Chinese family with CARASIL was obtained in the Department of Neurology in The First Affiliated Hospital of China Medical University, Shenyang, China, in December 2010, and a detailed medical history was obtained for family members. CARASIL was diagnosed according to previously described criteria, including early adulthood onset of subcortical infarcts, alopecia, spondylosis and progressive cognitive impairment. [1] [2] [3] [12] [13] [14] Healthy control subjects (50% male) were recruited from outpatient clinics at The First Affiliated Hospital of China Medical University between December 2010 and July 2012. Members of the CARASIL pedigree and control subjects were all of Chinese ancestry and came from China. Subjects included in this study provided written informed consent, and the study protocol was approved by the medical ethics committee of The First Affiliated Hospital of China Medical University.
Mutation analysis
Genomic DNA was extracted from peripheral leukocytes of fresh blood samples taken from the proband (IV 6 , Figure 1 ), the parents of the proband (III 2 and III 7 , Figure 1 ) and healthy control subjects, using a standard proteinase K digestion and phenolchloroform method.
All nine exons in the HTRA1 gene were amplified from the proband and parental genomic DNA by polymerase chain reaction (PCR) using the geneAmp PCR System 2700 thermocycler (Perkin Elmer, Shelton, CT, USA). The primer pairs (Table 1) were designed for exons 1-9 of the HTRA1 gene using Primer 5.0 software for Windows Õ (Premier Biosoft International, Palo Alto, CA, USA), according to a previously published sequence (GenBank Õ Accession No. NG011554; http://www.ensembl.org). Each 25 ml PCR reaction contained 60 ng of genomic DNA, 5 pmol of each forward and reverse primer, 5 mmol dNTP and 2.5 U of Taq Polymerase (Takara Biotechnology, Dalian, China) in a 1 Â reaction buffer (Takara Biotechnology, Dalian, China). The PCR reaction comprised denaturation at 95 C for 5 min, followed by 35 cycles of 95 C for 30-40 s, 57-63 C for 30 s, and 72 C for 30-40 s (depending on which segment in HTRA1 was amplified) and a final elongation step at 72 C for 10 min. PCR products were purified by gel electrophoresis and sequenced bidirectionally with an ABI PRISM TM 3730XL DNA Analyzer (Applied Biosystems, Foster City, CA, USA). The data were analyzed using Chromas 2.22 chromatogram file editor software (Technelysium Pty Ltd, Tewantin, Queensland, Australia). Healthy control subjects were screened by amplifying and bidirectionally sequencing exon 4 of the HTRA1 gene.
The base substitutions and mutations in the HTRA1 gene were described and numbered according to criteria provided by the Ensembl genome browser (http://www. ensembl.org).
Three-dimensional modelling of HTRA1
PolyPhen-2 software (http://geneics.bwh. harvard.edu/pph2/) 15 was used to predict whether the mutations within the HTRA1 gene would have damaging effects on serine protease HTRA1. To investigate the effect of the novel missense mutation p.P285L in serine protease HTRA1, two three-dimensional structures of serine protease HTRA1, either with or without the p.P285L mutation, were modelled. The two variants were compared: 285P and 285L. The protein data bank (PDB) (http://www.rcsb.org/pdb/ home/home.do) was searched for homology between the target sequence and possible template sequences. The optimum template sequence, 3NZI (a structure of human serine protease HTRA1, which has a sequence homology of 100% with the spanned region E160 to R370 of serine protease HTRA1) was selected using Position-Specific Iterative (PSI)-Basic Local Alignment Search Tool (BLAST). 16 The multiple sequence alignment Clustal W algorithm was then used to optimize the alignments of the target protein sequence and the template protein sequence. 17 The two three-dimensional models of the target sequences were then generated using MODELLER9 v11 software. 18 SWISS PDB VIEWER software (V4.10) was used to display and assess the models, which were then evaluated using ProSA-web. 19 No difference was found between the two models. The root mean square calculated between the two backbone atoms from the two models was low (0.90 Å ), and a Ramachandran plot suggested that 490% of the atoms in the two models were in permitted zones, indicating that the two models were accurate.
Results
The proband was a 26-year-old woman with the family pedigree shown in Figure 1 . No subject in this pedigree had hypertension, diabetes mellitus, heart disease or Table 1 . Forward (F) and reverse (R) primers used to amplify and sequence exons 1-9 of the high-temperature requirement A serine peptidase 1 (HTRA1) gene (two sets of primer pairs are shown for exon 9).
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adrenoleukodystrophy. The older male sibling of the proband was born with sparse hair and gradually developed alopecia. By age 24 years, he had right limb disability, lumbar pain and spastic gait. He underwent surgery for cervical intervertebral disc herniation and died within 5 years of the operation. Amentia, paralysis and faecal and urinary incontinence gradually developed during these 5 years. One older female sibling of the proband died of lung cancer and the other older female sibling died in an accident.
Progressive alopecia was evident in the proband from birth (Figure 2A ).
The proband developed right limb disability and lumbar pain following sleep at age 23 years, and had a spastic gait from then on. Eighteen months later, the proband became lethargic, which was associated with urinary incontinence, uncommunicativeness and absence of hunger. Over the following month, the lethargy and poor memory worsened, while the other symptoms improved. The patient relapsed by the end of the following year.
On detailed examination, the proband showed a decline in intelligence, dysarthria, dystaxia, spastic gait, increased deep-tendon reflexes at the extremities with clonus and bilateral positive Babinski sign. Muscular tension in the extremities was slightly increased.
The Mini-Mental State Examination score was 8 and education level was primary school, year 2. Haemograms, biochemical analysis and electrocardiograms were within normal parameters. Electroencephalography demonstrated diffuse slow waves, predominantly in the temporal and occipital areas. Brain magnetic resonance imaging (MRI) showed multiple lacunar infarcts and diffuse leukoencephalopathy ( Figure 2B ). Cervical and lumbar MRI demonstrated retrogression of vertebrae and intervertebral discs, and prolapse of intervertebral discs (C2-T1 and L1-2) ( Figure 2C ). The 65-year-old father of the proband was also born with alopecia and had developed left limb disability at age 63 years. Examination showed a spastic gait, increased muscular tension in the left extremities and left positive Babinski sign. Brain computed tomography (CT) scans showed multiple lacunar infarcts and diffuse leukoencephalopathy. Other members in this family differed from the proband and her older male sibling, and did not show symptoms of CARASIL.
Bidirectional sequencing of segments containing exons 1-9 of the HTRA1 gene revealed a homozygous missense mutation in exon 4 of the HTRA1 gene in the proband and an identical heterozygous mutation in the parents of the proband ( Figure 3A-C) . This mutation, c.854C 4 T, resulted in an amino acid change from proline to leucine (p.P285L). The mutation was absent in 130 healthy control subjects (260 chromosomes, 50% male) and from single nucleotide polymorphism (SNP) databases. No mutations were detected by bidirectional sequencing of exons 1-3 or 5-9 of the HTRA1 gene in either the proband or her parents.
Alignment of the amino acid sequence surrounding the novel mutation (p.P285L) in exon 4 in the HTRA1 gene showed that the proline at position 285 is located in a highly conserved region of serine protease HTRA1 in humans and in other species (http://www.ensembl.org) ( Table 2) . This mutation was predicted to be probably damaging by Polyphen-2 software (score 0.995; sensitivity 0.45/specificity 0.96). 15 Three-dimensional modelling showed that the novel mutation (p.P285L) in a region of the serine protease HTRA1 protein could attenuate the hydrogen bond between S284 and S287 residues, based on the distance and the angles between the atoms (Figure 4 ).
Discussion
The Chinese proband with CARASIL in the present study was found to be homozygous for a novel mutation (c.854C 4 T) identified in exon 4 of the HTRA1 gene, which resulted in an amino acid change from proline to leucine (p.P285L). The parents of the proband were found to be heterozygous for the same mutation, which was absent in 130 healthy control individuals (260 control chromosomes) and from SNP databases. Bidirectional sequencing revealed no mutations in the other exons of the HTRA1 gene in either the proband or her parents. The mutation in this CARASIL pedigree followed the genetic pattern of autosomal recessive inheritance and further confirmed the diagnosis of CARASIL.
The change in amino acid sequence (p.P285L) caused by the novel mutation in the present study was found to be located in a highly conserved region of serine protease HTRA1 in different species. 12 This mutation was predicted to be probably damaging by Polyphen-2 software. 15 The modelling results showed that the novel mutation (p.P285L) in the HTRA1 protein may attenuate the hydrogen bond between S284 and S287 residues. The weaker hydrogen bond may alter the spatial formation, the electrostatic potential and the stability of the protein, which may alter the function of the protein. The results of the present study implied that the change from proline to leucine (p.P285L) might alter a critical molecular structure, potentially impairing the activity of serine protease HTRA1. Previous studies indicated that missense mutations in exon 3 and exon 4 of the HTRA1 gene (p.A252T, p.R274Q and p.V297M) reduced the level of serine protease HTRA1 activity and of HTRA1 expression, which led to complete or less efficient suppression of signalling by TGF-b family members. 2, 13, 20, 21 The increased TGF-b signalling resulted in vascular fibrosis by increased synthesis of fibrous proteins including fibronectin and versican, which could be detected in vascular wall biopsies of patients with CARASIL. 2, [22] [23] [24] A nonsense mutation, R302X, in the HTRA1 gene of a patient with CARASIL resulted in decreased protease activity compared with the wild type, while another nonsense mutation in the HTRA1 gene, R370X, demonstrated loss of inhibition of signalling by TGF-b family members. 2 It has been suggested that the disinhibition of TGF-b family signalling associated with mutations in the HTRA1 gene is the molecular basis of CARASIL. 2 Like the novel missense mutation found in the present study, four of the seven mutations identified in exons 3, 4 and 6 of the HTRA1 gene in patients with CARASIL were found in exon 4. 2, [12] [13] [14] The proband and her older male sibling both showed young-adult-onset alopecia, spondylosis, leukoencephalopathy and progressive cognitive impairment. These symptoms were in accordance with the characteristics of CARASIL observed in the clinic, with alopecia and spondylosis being exclusive symptoms of CARASIL, distinct from other cerebral small-vessel diseases. 2, [25] [26] [27] [28] Alopecia and spondylosis are associated with signalling by TGF-b family members and with the HTRA1 gene. 2, 25, 26 In the present study, both parents of the proband were heterozygous for Table 2 . Conservation of regional amino acid residues in the high-temperature requirement A serine peptidase 1 (HTRA1) gene (http://www.ensembl.org).
Species Gene
Amino acid 252 274 285 295 297 364
The novel mutation p.P285L is located in a highly conserved region of the protein. Other missense mutations associated with cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) are also listed.
the p.P285L mutation, and symptoms of alopecia and leukoencephalopathy were moderate in the father. A previous study noted similar manifestations of the mutation p.G295R in exon 4 of HTRA1 gene in a separate CARASIL pedigree. 12 Studies have also shown that different mutations can lead to different clinical features, with mutations p.A252T and p.R274Q in exon 4 of the HTRA1 gene in a CARASIL pedigree not showing symptoms of alopecia. 2, 13 Some studies found an association between a SNP in the HTRA1 gene and the neovascular form of age-related macular degeneration. 29, 30 These results suggest that future follow-up studies, involving more patients, should include investigation of the presence of heterozygous mutations in HTRA1, in older patients with leukoencephalopathy.
The present study indicates that a novel homozygous mutation c.854C 4 T in exon 4 of the HTRA1 gene is related to CARASIL. This result expands the spectrum of mutations in HTRA1 known to be associated with CARASIL, and may contribute to the Figure 4 . Two three-dimensional models showing portions of the serine protease HTRA1 protein coded by exon 4 of the high-temperature requirement A serine peptidase 1 (HTRA1) gene, generated by homology modelling using MODELLER9 v11 software. The residue P285 or L285 is in one colour. (A) Hydrogen bond in green is between S284 and S287 residues in the wild type serine protease HTRA1 protein (285P, arrowheads); (B) the weaker hydrogen bond in grey is between S284 and S287 residues in the mutated serine protease HTRA1 protein (285L, arrowheads). positive diagnosis of CARASIL and genetic counselling in the clinic. The CARASILrelated mutations found in the present and other studies indicate that exon 4 of the HTRA1 gene may be a hotspot region for mutations that cause CARASIL. 2, [12] [13] [14] Future studies on the c.854C 4 T mutation in exon 4 of HTRA1 should aim to elucidate the pathogenesis of CARASIL in order to improve CARASIL-related therapy.
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